
Clinical trials in chronic kidney disease enrich the trial population for patients with a high renal and cardiovascular risk by including patients with elevated urinary albumin creatinine ratio (UACR) and low estimated glomerular filtration rate (eGFR). Approximately half of all screen failures in these trials are attributed to UACR and eGFR outside predefined limits. This may in part be attributed to the high intra‐individual variation in these parameters. Our aim was to test whether a screening approach with more flexible UACR and eGFR thresholds would decrease screen failure rate without negatively impacting on the event rate and overall study duration. We performed a post‐hoc analysis of the ALTITUDE trial...
Like
Save
Share